

Quarterly Shareholder Report | March 2026

Syntara Limited (ASX: SNT), a clinical-stage drug development company, is pleased to provide a summary of its activities for the quarter ended 31 March 2026:

- **Post quarter end, Syntara announced it had received positive feedback from the US FDA, following a Type C meeting, which supports the Phase 2b trial design for its lead candidate amsulostat in the treatment of myelofibrosis**
- **Final patient recruited into Phase 2 study of first-in-class neuro-targeted anti-inflammatory therapy, SNT-4728, to treat isolated REM Sleep Behaviour Disorder (iRBD)**
 - **Top-line results are expected in Q2 CY26**
- **Garvan Institute of Medical Research secures A\$3 million MRFF grant funding for studies in advanced pancreatic cancer, including Syntara's amsulostat with standard-of-care chemotherapy**
 - **Recruitment expected to begin 2H 2026 across major NSW cancer centres**
- **A\$1.7m SNT-4728 milestone payment received from Parkinson's UK**
- **Proforma cash balance at 31 March 2026 of \$16.9¹ million**
- **Post quarter end, the Company announced a successful capital raising whereby it has received firm commitments for an addition \$8.0 million via a two-tranche institutional placement, and a further \$2.0m to be offered under a share purchase plan.**

Syntara CEO Gary Phillips said:

"The March quarter was highly productive for Syntara, with strong progress across our clinical programs and additional non-dilutive funding received. This has been reinforced by a placement of new shares this week to raise \$8m, with a further \$2m open to existing shareholders as part of a share purchase plan.

The capital raising was prudent after the positive feedback received from the FDA, paving the way to prepare amsulostat for a Phase 2b trial in approximately 100 patients.

¹ Includes \$8m Placement proceeds (before costs) assuming Tranche 2 of the Placement is approved by shareholders from April 2026 capital raise.

Additionally, during the quarter, recruitment was completed in our Phase 2 iRBD trial of SNT-4728, a key milestone, with top-line data anticipated in Q2 CY26. These results have the potential to validate our approach of targeting neuroinflammation at the earliest stages of neurodegenerative disease, and we believe positive results will be of strong interest to Parkinson's UK and the broader pharmaceutical community.

We were also delighted to see the Garvan Institute secure \$3 million in MRFF funding to advance amsulostat into a Phase 1/2 clinical trial in advanced pancreatic cancer, a program that requires no cash contribution from Syntara. This brings our total non-dilutive clinical funding to \$11.5 million across four studies, which is a strong endorsement of the quality of the science underpinning our pipeline.

With five clinical data readouts expected during calendar year 2026, backed by an influx of new funding, Syntara is well positioned to deliver a transformative year."

CLINICAL PIPELINE UPDATES

Amsulostat on target for Phase 2b trial following positive FDA feedback

Subsequent to the end of the quarter, Syntara announced it had received positive feedback from the U.S. Food and Drug Administration (FDA) after a constructive in person Type C meeting regarding the planned Phase 2b clinical trial of its lead candidate, amsulostat, for the treatment of patients with myelofibrosis (MF) who have had an inadequate response to standard of care.

Following a review of amsulostat's development to date, the FDA supported the proposed Phase 2b study design and provided guidance on the detail of the study and overall development pathway for amsulostat. This feedback enables progression into late-stage clinical development and creates opportunity for further engagement with potential commercial partners.

The Phase 2b study will be a double blind, placebo-controlled study of amsulostat added to standard of care (JAK inhibition) for patients who have had an inadequate response. The primary endpoint will be achievement of 50% reduction in total symptom score (TSS50) after 9 months of treatment. Subject to final protocol review, the number of patients to be studied is expected to be approximately 100.

SNT-4728 completes recruitment in Phase 2 sleep disorder trial supported by Parkinson's UK

During the quarter, the Company announced the completion of recruitment into its randomised, double-blind, placebo-controlled Phase 2 clinical trial of SNT-4728 in patients with isolated REM Sleep Behaviour Disorder (iRBD). With all patients enrolled and undergoing a three-month treatment period, top-line results are expected in Q2 CY26.

iRBD is estimated to affect approximately 2% of people over 50 years of age, and long-term observational studies suggest that up to 90% of individuals with the condition subsequently develop a neurodegenerative disease such as Parkinson's disease or Dementia with Lewy bodies, making it the strongest clinical predictor of these disorders. The multi-centre study is evaluating SNT-4728, Syntara's first-in-class neuro-targeted anti-inflammatory therapy, across two complementary

dimensions: advanced brain imaging at baseline and after the 12-week treatment period to assess whether the drug reduces neuroinflammation in key brain regions implicated in progression to neurodegeneration, and other secondary and exploratory endpoints, including the examination of whether SNT-4728 improves the clinical symptoms of iRBD.

Evidence of reduced neuroinflammation on brain imaging would support the broader hypothesis that SNT-4728 has the potential to modify disease biology during the prodromal phase of neurodegeneration.

Amsulostat in pancreatic cancer Phase 1/2 clinical trial in collaboration with the Garvan, funded by MRFF

In January, the Garvan Institute of Medical Research was awarded a \$3 million grant under the Australian Government's Medical Research Future Fund (MRFF) to conduct two multicentre clinical studies in advanced pancreatic cancer. One of these studies will evaluate Syntara's investigational anti-fibrotic LOX inhibitor amsulostat in combination with standard-of-care chemotherapy.

Under the collaboration, Syntara will contribute drug supply along with scientific and clinical expertise, with no cash funding required from the company. The program builds on preclinical research led by the Garvan Institute and published in *Nature Cancer*, which demonstrated that targeting tumour fibrosis weakens the dense stromal barrier surrounding pancreatic tumours, allowing chemotherapy to penetrate more effectively and reducing cancer cell invasion and metastasis. Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with this fibrous barrier being a key driver of treatment resistance.

Recruitment is expected to commence in 2H 2026 across leading NSW cancer centres. Beyond assessing safety and clinical activity, the studies will incorporate a precision medicine approach involving deep molecular and genetic profiling of tumour and blood samples to identify biomarkers and patient subgroups most likely to benefit from treatment.

This MRFF-supported study brings Syntara's total non-dilutive clinical funding to \$11.5 million across four studies, and the approach of targeting tumour fibrosis may also hold broader implications for other solid cancers, including certain breast, liver and lung cancers.

FUNDRAISING ACTIVITIES

Placement of A\$8.0m and \$2.0m share purchase plan

Subsequent to the end of the quarter, the Company announced it had received firm commitments from existing and new institutional and sophisticated investors to raise A\$8.0 million (before costs) by way of a two-tranche institutional placement. The Company will also initiate a non-underwritten share purchase plan (SPP) to existing eligible shareholders to raise approximately A\$2.0 million.

Placement proceeds will provide a cash runway to Q3 2027 and be applied to:

- Trial readouts and licensing discussions – funding five key clinical trial readouts over CY2026 and to progress current licensing discussions across the pipeline.

- Phase 2b MF study preparation – preparatory work, including protocol finalisation, CRO selection, trial site negotiations, formulation development, and clinical trial supplies.
- Patent suite – strengthening the Company's global leading pan-LOX patent suite and add potential to exploit multiple indications.
- Offer costs – funding costs associated with the Offer.

The Capital Raising comprised an institutional placement to raise A\$8.0 million to existing and new institutional and sophisticated investors and the SPP to existing eligible shareholders in Australia and New Zealand to raise A\$2.0 million, both at A\$0.027 per new share.

A\$1.7m SNT-4728 milestone payment from Parkinson's UK

In March, Syntara received a milestone payment of approximately A\$1.7 million (£900,000) from Parkinson's UK, triggered by dosing of the final patient in its Phase 2 clinical trial of SNT-4728.

The payment forms part of Parkinson's UK's funding commitment to support the development of SNT-4728, which is being evaluated as a potential treatment targeting neuroinflammation associated with early-stage Parkinson's disease.

Top-line results from the trial, including both safety and efficacy endpoints, are expected in Q2 CY26. Syntara will be eligible to receive a further A\$0.45 million (£250,000) milestone payment from Parkinson's UK upon project completion.

CORPORATE UPDATES

2026 Outlook Webinar

Chief Executive Officer Gary Phillips and Non-Executive Director Hashan De Silva hosted an investor webinar to provide the company outlook and commentary on the Company's extensive clinical pipeline for 2026. A replay of the webinar is available at: <https://youtu.be/XiWqRdZKWhE>

NWR Virtual Healthcare Conference

Later in the quarter, Chief Executive Officer Gary Phillips also participated in the NWR Virtual Healthcare Conference, where he provided an update on the Company's ongoing clinical trial programs. A replay of his presentation is available at: <https://youtu.be/NMG7hCfj8-I?si=fbBpEaoemIWJ5QQQ>

Euroz Hartleys Healthcare Forum

CEO Gary Phillips presented at the Euroz Hartleys Healthcare Forum in February. [Click here to view the presentation slides for the event.](#)

Change of Company Secretary

In January, existing Chief Financial Officer, Mr Tim Luscombe was appointed as Company Secretary of Syntara.

This followed Mr Cameron Billingsley notifying the Board of his resignation as Company Secretary. Mr Billingsley will continue to provide external general counsel services to Syntara.

FINANCIAL

Financial performance

At the end of the March 2026 quarter Syntara had a closing cash balance of \$8.9 million, compared to \$10.5 million at 31 December 2025. The net cash outflow of \$1.6 million driven by the operating cashflows. Post quarter end, the Company announced that it had received firm commitments from existing and new institutional and sophisticated investors to raise A\$8.0 million (before costs) by way of a two-tranche institutional placement, giving it a proforma closing cash balance of \$16.9² million. The Company intends to also conduct a non-underwritten share purchase plan to existing eligible shareholders at the record date to raise approximately A\$2.0 million.

The net cash outflows in operating activities during the quarter was \$1.6 million (included the receipt of \$1.7 million of proceeds from Parkinson's UK grant for the iRBD trial), compared with \$3.8 million for the previous quarter to 31 December 2025.

R&D (\$2.0 million) and staff costs (\$1.3 million) totalling \$3.3 million represented 88% of the Company's total net operating cash outflows. Of the \$2.0 million direct R&D expenditure the majority was represented by expenditure on the Company's ongoing major clinical programs:

- the Phase 2a trial in MF;
- the Phase 1a/b trial for hypertrophic scars;
- the SATELLITE Phase 1c trial for keloid scars; and
- the iRBD trial, where the majority of the costs of this trial are funded by a grant from Parkinson's UK.

Amounts owed from the sale of the mannitol respiratory business

Syntara sold its mannitol respiratory business unit (MBU) in the fourth quarter of 2023 to Arna Pharma Pty Ltd (Arna Pharma). A post completion transition period has now ended and the MBU and Frenchs Forest facility are now fully separated from Syntara. Syntara's research laboratories and corporate offices are now subleased at Frenchs Forest from Arna Pharma.

As previously advised, Arna Pharma challenged the contractual payment obligations claimed by Syntara from the sale. Since that time the parties have made further progress in reconciling the amounts owing and some payments have been made. The Company continues to pursue amounts owing by the acquiror and expects to receive further payments over the course of the financial year. There remains significant uncertainty in relation to the quantum and timing of amounts that will be received.

After amounts already paid by Arna Pharma (~\$6.1 million) and various offsets to

² Includes \$8m Placement proceeds (before costs) assuming Tranche 2 of the Placement is approved by shareholders from April 2026 capital raise.

expenses incurred by Syntara to Arna, the amounts currently claimed by Syntara at 31 March 2026 have been substantially reduced and now total ~\$0.7 million.

Payments to Related Entities

In accordance with Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of Appendix 4C incorporates directors' fees, salaries and superannuation. Payments made for the quarter total \$191,000 and relate to payments to the CEO/Managing Director in accordance with employment contracts, as well as payments to the Non-Executive Directors.

#ENDS#

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome have been initiated.

Syntara is also advancing topical pan-LOX inhibitors with SNT-9465 in a Phase 1a/b study of hypertrophic scars and continuing the ongoing collaboration with Professor Fiona Wood and the University of Western Australia studying SNT-6302 in keloid scars. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

SOURCE:

Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:
Syntara Limited Disclosure Committee.

CONTACT:

Syntara investor / media relations:
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST [HERE](#)



Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

entity

SYNTARA LIMITED

ended ("current quarter")

75 082 811 630

31 March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	56	167
1.2 Payments for		
(a) research and development	(1,958)	(8,503)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(1,255)	(4,341)
(f) administration and corporate costs	(441)	(1,326)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	1	68
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	1,750	7,380
1.8 Other (provide details if material)	158	416
1.9 Net cash from / (used in) operating activities	(1,689)	(6,139)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(2)	(2)
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(2)	(2)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (repayment of lease liability)	-	(88)
3.10	Net cash from / (used in) financing activities	-	(88)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	10,515	15,076
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,689)	(6,139)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(2)	(2)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(88)
4.5	Effect of movement in exchange rates on cash held	34	11
4.6	Cash and cash equivalents at end of period	8,858	8,858

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,128	865
5.2	Call deposits	7,730	9,650
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	8,858	10,515

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	191
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

The amount at 6.1 includes Director fees and salary (including short term incentives and superannuation) for the CEO and Managing Director and Non-Executive Directors.

7.	ing facilities <i>Term "facility" includes all forms of financing arrangements entered into by the entity. As necessary for an understanding of the sources of financing, the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	Total financing facilities	-	-
7.5	Unused financing facilities available at quarter end	-	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	N/A		

8.	ed cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,689))
8.2	Cash and cash equivalents at quarter end (item 4.6)	8,858
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	8,858
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	5.2
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

30 April 2026

Date:

The Board of Directors

Authorised by:
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.